Last reviewed · How we verify
NCT07010198
Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City
trial testing Quantitative HBeAg Testing in Hepatocellular Cancer (HCC) in 4,500 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Zhongshan People's Hospital, Guangdong, China |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 4,500 |
| Start date | 1 March 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Quantitative HBeAg Testing
- Measurement Indicators Required for Risk Scoring in HCC Screening Strategies — full drug profile →
- Follow-Up Monitoring Parameters — full drug profile →
Conditions studied
- Hepatocellular Cancer (HCC) — all drugs for Hepatocellular Cancer (HCC) →
Sponsor
Zhongshan People's Hospital, Guangdong, China
Who can join
35 and older, any sex, with Hepatocellular Cancer (HCC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Based on the preliminary retrospective validation of the efficacy of five HCC screening strategies(including conventional AFP combined with ultrasound-based general screening strategy, REACH-B, AGED, aMAPand aMAP 3.0 risk score) in Xiaolan Town, a head-to-head comparison for HCC screening is conducted in Zhongshan City, Guangdong Province. The study is a prospective, single-center, head-to-head trial aiming to enroll 4,500 HBsAg-positive individuals. It adopts a two-phase design of "HBV screening first, followed by HCC surveillance":Phase I: Recruitment of age-eligible populations at study sites for HBsAg screening to establish a high-risk cohort positive for hepatitis B surface antigen.Phase II: Implementation of uniform HCC surveillance (AFP combined with liver ultrasound every six months) for HBsAg-positive individuals, with concurrent application of different risk stratification models to evaluate risk levels and screening efficacy for each participant during follow-up.Furthurmore, based on baseline biological information and follow-up data, the study also aims to explore the development of a more effective risk prediction model for HCC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07010198
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Zhongshan People's Hospital, Guangdong, China trials
Trials by the same sponsor.
- NCT06282497 — Xerostomia-optimised IMRT Versus Standard IMRT in NPC · NA · recruiting
- NCT05994170 — Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma · NA · recruiting
- NCT05990946 — Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assist · NA · recruiting
- NCT05981157 — Anrotinib and Tirelizumab in First-line Treatment of RM-NPC · Phase 2 · unknown
- NCT05884983 — Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07010198 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongshan People's Hospital, Guangdong, China
- Last refreshed: 8 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07010198.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing